Compacted information on mushroom cultivation in relation to production, performance, problems and prospects is very important for developing this sector. So, the aim of the review paper is to compile information on mushroom cultivation in Bangladesh. Mushroom production is increasing due to high demand of domestic market and export potentiality. In Bangladesh 40000 MT mushrooms are produced during 2018-19. Oyster, Reishi, Milky, Button, Straw and Shiitake mushrooms are most preferable species and cultivated by the farmers; but the maximum cultivation is confined to oyster mushroom (Pleurotus spp.) which are grown throughout the year. Mostly young aged educated people and rural women are adopting mushroom farming as commercial basis in Bangladesh. The study revealed that mushroom production is easy work because it requires only a little technical efficiency and a highly profitable agribusiness as evident for its lucrative benefit cost ratio (BCR 1.55-4.25). Although mushrooms production increased, there are some problems confronting by the mushroom growers during cultivation and marketing including lack of cultivation house, unavailability of good spawn, capital shortage, lack of equipment’s, lack of available market and promotion in local level, lack of storage facilities etc. which are needed to be addressed for further development of this sector. There is enormous opportunity of expanding mushroom farming throughout the country. Considering the country’s limited land, over and unemployed population, strengthening the production of mushroom could be one of the sustainable options for the development of rural economy. Development of this sector would also improve the diversified business and employment opportunities both in the rural and semi-urban areas.

Predicting changes in land use land cover and seasonal land surface temperature using multi-temporal landsat images in the northwest region of Bangladesh, HELIYON,

Several plants have traditionally been used since antiquity to treat various gastroenteritis and respiratory symptoms similar to COVID-19 outcomes. The common symptoms of COVID-19 include fever or chills, cold, cough, flu, headache, diarrhoea, tiredness/fatigue, sore throat, loss of taste or smell, asthma, shortness of breath, or difficulty breathing, etc. This study aims to find out the plants and plant-derived products which are being used by the COVID-19 infected patients in Bangladesh and how those plants are being used for the management of COVID-19 symptoms. In this study, online and partially in-person survey interviews were carried out among Bangladeshi respondents. We selected Bangladeshi COVID-19 patients who were detected Coronavirus positive (+) by RT-PCR nucleic acid test and later recovered. Furthermore, identified plant species from the surveys were thoroughly investigated for safety and efficacy based on the previous ethnomedicinal usage reports. Based on the published data, they were also reviewed for their significant potentialities as antiviral, anti-inflammatory, and immunomodulatory agents. We explored comprehensive information about a total of 26 plant species, belonging to 23 genera and 17 different botanical families, used in COVID-19 treatment as home remedies by the respondents. Most of the plants and plant-derived products were collected directly from the local marketplace. According to our survey results, greatly top 5 cited plant species measured as per the highest RFC value are Camellia sinensis (1.0) > Allium sativum (0.984) > Azadirachta indica (0.966) > Zingiber officinale (0.966) > Syzygium aromaticum (0.943). Previously published ethnomedicinal usage reports, antiviral, anti-inflammatory, and immunomodulatory activity of the concerned plant species also support our results. Thus, the survey and review analysis simultaneously reveals that these reported plants and plant-derived products might be promising candidates for the treatment of COVID-19. Moreover, this study clarifies the reported plants for their safety during COVID-19 management and thereby supporting them to include in any future pre-clinical and clinical investigation for developing herbal COVID-19 therapeutics.

No abstract

No abstract